Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...

Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous squamous cell carcinoma and data on linvoseltamab for relapsed or refractory multiple myeloma. Other research ...

Sanofi said the results are strong enough to support a new indication in the US and EU for Libtayo, a PD-1 inhibitor that is already FDA-approved in advanced cutaneous squamous cell carcinoma.

Highlights from the ASCO presentations will include results from the Phase 3 C-POST trial, which explores the adjuvant use of PD-1 inhibitor Libtayo in high-risk cutaneous squamous cell carcinoma ...

A study demonstrates that radiologic imaging significantly alters management strategies in nearly half of high-risk cutaneous ...

Oncology Programs The Company submitted an sBLA to the FDA and a regulatory application in the EU for Libtayo (cemiplimab) in adjuvant CSCC based upon data from a Phase 3 trial which demonstrated ...

The following is a summary of “Lymphovascular invasion is an independent predictor of metastasis and disease-specific death in cutaneous squamous cell carcinoma: a multicenter retrospective study,” ...